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BACKGROUND. Radiation therapy (RT), a critical component of breast-conserving
therapy for breast cancer, has been associated with coronary artery disease (CAD)
in numerous older studies, but the risk may be lower with modern techniques.
METHODS. Observed rates of cardiac events in 828 patients treated with breast-con-
serving surgery and RT at the University of Michigan were compared with expected
rates. Relations between potential risk factors and actuarial rates of first CAD event
were analyzed.
RESULTS. Observed risks of cardiac events were lower than expected. The standar-
dized incidence ratio (SIR) of myocardial infarction (MI) was 0.44 (95% confidence
interval [CI]: 0.21–0.70). The SIR of MI or CAD requiring intervention was 0.50 (95%
CI: 0.27–0.68). With a median follow-up of 6.8 years, 12 (1.4%) patients had at least
1 MI on follow-up and 20 (2.4%) had at least 1 MI or CAD requiring intervention. Me-
dian age at first cardiac event was 75.9 years (range, 43.1–91.5). Median interval from
RT to occurrence of the first cardiac event was 3.7 years (range, 13 days to 15.4 years).
The 10-year cumulative incidence of MI was 1.2% and cumulative incidence of MI or
CAD requiring intervention was 2.7%. On multivariate analysis, age, diabetes melli-
tus, active smoking, and laterality of RT were significant predictors of MI. Age and
active smoking were significant predictors of MI or CAD requiring intervention.
CONCLUSIONS. Patients in this series had lower risk of ischemic cardiac events than
expected. Although small in absolute magnitude, patients radiated to the left side
did have a statistically significant increased risk of MI. These findings support fur-
ther investigation of techniques to minimize the long-term cardiac risks faced by
breast cancer patients. Cancer 2007;109:650–7.  2007 American Cancer Society.
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R adiation therapy (RT), a critical component of breast-conservingtherapy for breast cancer, has been associated with ischemic
heart disease in numerous studies.1–5 Meta-analysis by the Early
Breast Cancer Trialists Group indicated that breast cancer patients
receiving RT in clinical trials conducted over the past several dec-
ades have had significant excess mortality from heart disease (rate
ratio 1.27, P ¼ .0001).6 However, caution must be employed when
extrapolating the results of this meta-analysis, which included older
trials using outdated radiation techniques, to estimate risks for
patients treated in the modern era.
Indeed, several single-institution studies have retrospectively
compared patients treated to the left and right sides of the chest
and failed to document increased risk in series of patients treated
with more modern techniques.7,8 Furthermore, a large population-
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based analysis of women treated for breast cancer
from 1973–1989 suggested that the increased risk of
ischemic heart disease associated with RT has
decreased over time.9 The study, based on data in
the Surveillance, Epidemiology, and End-Results (SEER)
registries, compared ischemic heart disease mortality
in patients with left- vs right-sided radiation treat-
ments, hypothesizing that any difference in risk
would be related to the differential cardiac doses
received by the 2 groups. In 1979 the hazard ratio for
women with left-sided treatment was 1.5, but the
hazard of death from ischemic heart disease de-
creased by 6% with each succeeding year. Moreover,
in a separate SEER-based analysis, when investiga-
tors compared cardiac morbidity in breast cancer
patients treated with adjuvant radiation therapy to
the left vs right side from 1986–1993 they found no
significant differences in rates of hospitalization for
ischemic heart disease, valvular heart disease, con-
duction abnormalities, or heart failure.10 Still, it has
been noted that even patients treated with RT to the
right side may receive some cardiac irradiation if
their internal mammary nodes were targeted and,
therefore, comparison of patients with left- and right-
sided disease may underestimate the potential toxic-
ity of irradiation.11 Furthermore, potential inacc-
uracies may exist in the SEER data, particularly
regarding the use of radiation therapy, leading some
to desire confirmation from more detailed, albeit
smaller, databases from single institutions.12
A retrospective review of rates of cardiovascular
deaths in a population treated with postmastectomy
radiation between 1975 and 1994 at a single institution
documented very low rates of death from myocardial
infarction (MI).13 Yet in light of another SEER-based
study that revealed breast cancer survivors to have a
diminished risk of acute MI requiring hospitalization,14
it is difficult to determine whether the low rate of
events in that series simply reflects a lower baseline risk
of ischemic cardiac disease in the breast cancer patient
population, or whether it truly indicates that radiation
therapy administered during that time period had little
effect on risk. In fact, cardiac perfusion defects have
been documented even in patients treated from 1998–
2002 with advanced techniques of 3-dimensional plan-
ning,15 although the clinical consequences of these
changes in cardiac perfusion are not yet clear. More-
over, a recent retrospective study of patients treated
from 1977 to 1994 at a single institution found a signifi-
cant increase in posttreatment development of ische-
mic cardiac disease in left-sided patients, and this
series notably included only patients treated with a
contemporary tangential irradiation technique.12 Fur-
ther research in this area is therefore warranted.
In this study we assessed the incidence of ische-
mic cardiac events and associated risk factors in a
series of patients treated with breast-conserving sur-
gery and RT for early-stage breast cancer at a single
institution over the past 2 decades. We also com-
pared rates of ischemic cardiac disease in this popu-
lation to the rates in an age-, race-, and sex-matched
control population.
MATERIALS AND METHODS
From 1984 to 2000, 867 consecutive patients with
AJCC 1999 stage I or II breast cancer were treated
with breast-conserving surgery and RT at the Univer-
sity of Michigan Hospital.16 The vast majority of
these patients were clinically simulated with fluoro-
scopic guidance. The University of Michigan began
to utilize routine computed tomography (CT)-based
planning for all breast cancer patients in February
2000. CT planning, however, was used in node-posi-
tive patients from November 1997 onward to incor-
porate the internal mammary nodes in interspaces
1–3 in the target volume after the publication of the
Danish and Canadian postmastectomy radiotherapy
trials.17–19 Megavoltage linear accelerator-generated
photon beams were used for treatment.
After obtaining consent from the University of
Michigan Institutional Review Board to review patient
records for the outlined study, we reviewed these
patients’ inpatient and outpatient charts and found
that 841 of these patients had records sufficient to
determine the incidence of ischemic heart disease in
follow-up. Patients found on chart review to have
received other courses of radiation treatment to the
chest for recurrence or other causes were excluded
from all analyses. Patients with bilateral breast cancer
who received radiation treatment to both sides of the
chest were excluded from the comparison of left-
vs right-sided patients. Patient demographics were
documented, including age and race. Details of the
patients’ breast cancer treatment were also documen-
ted, as well as any systemic therapies received. Adju-
vant use of a systemic agent was defined as use of
such an agent within 1 year of breast cancer diagnosis.
Charts were reviewed to determine whether patients
had any established vascular risk factors at baseline
(before their radiation therapy), including hyperten-
sion, diabetes, hypercholesterolemia, smoking, his-
tory of coronary artery disease (CAD), or history of
stroke. Hypertension was established if it was docu-
mented in the patient’s history, if medications
included an antihypertensive agent for which there
was no other obvious indication, or if 2 blood pres-
sure readings in excess of 140 systolic or 90 diastolic
CAD in Radiated Breast CA Patients/Jagsi et al. 651
were recorded within 1 year of one another, without
other explanation. Diabetes was established if listed
in the history, if the patient was taking insulin or an
oral hypoglycemic agent, or if the laboratory value of
hemoglobin A1c exceeded 6.5. Hypercholesterolemia
was established if listed in the history, if the patient
was taking an antihyperlipidemic agent, if total fast-
ing serum cholesterol exceeded 220, or if fasting LDL
exceeded 160. Details of smoking history were re-
corded, including whether the patient had ever
smoked, start and quit dates, pack-years, and
whether the patient was actively smoking at the time
of RT. History of CAD was also noted, including prior
MI, prior percutaneous coronary intervention or
bypass surgery, catheterization-documented coronary
stenosis, or documented history of angina. History of
stroke was also assessed, including prior cerebrovas-
cular accident causing a clinical neurological deficit
of longer than 24 hours, infarction noted on brain
imaging, or history of transient ischemic attack with-
out persistent neurological deficit.
Charts were also reviewed to establish the devel-
opment of ischemic heart disease in follow-up. Two
categories of cardiac events were defined for analysis.
One was restricted to MI alone. The other included
either MI or CAD requiring percutaneous interven-
tion or bypass surgery.
Observed rates of cardiac events were compared
with expected age-, sex-, and race-specific rates to
obtain standardized incidence ratios (SIRs). Expected
rates were calculated from the National Hospital
Discharge Surveys (NHDS) annual cross-sectional,
population-based surveys of hospital discharge events
for the US civilian population, obtained from the
Centers for Disease Control and Prevention.20 For
purposes of this analysis, NHDS data from 1989
through 2003 were used to calculate the expected
rates of cardiac events. For each survey year the
NHDS database was queried by relevant ICD-9 diag-
nostic codes for the outcome of interest. Using the
survey weights, the total number of discharges for
the particular outcome of interest was calculated and
summed across all 15 surveys used. The total dis-
charges were totaled within 5-year age groups, which
overlapped with the age distribution for the observed
breast cancer patients. Five-year age groups started
at age 20–24 and continued through 95–99. The total
discharges were also totaled by the race category
assigned to the patient (white, black, or other). The
civilian population estimates for the US, published
by the US Census Bureau,21 for the survey years were
used as the denominator for rate calculations.
The person-years of follow-up in the University
of Michigan Radiation Oncology breast cancer data-
base were calculated from the date of initiation of
radiotherapy until the patient’s date of death or last
known contact date (defined strictly by the presence
of records adequate to establish whether cardiac
events had occurred). For each patient the person-
years of follow-up attributed to each 5-year age
group were calculated and the total person-years for
the study population were summed by race category.
The expected number of events for each age group
was calculated by multiplying the NHDS rate by the
total person-years for each age group. The expected
number of events was then summed for all age
groups to give an aggregate estimate. The observed
to expected ratios—or SIRs—were then calculated.
Confidence intervals (CIs) were calculated by itera-
tively resampling our population with replacement
(1000 samples), the bootstrap technique, and calcu-
lating the SIR for each sample. Ninety-five percent
CIs for the SIR estimates were constructed empiri-
cally using the 2.5th and 97.5th percentile of the
bootstrap distribution as the confidence limits.22
Next, actuarial curves were analyzed to examine
the relation between potential risk factors and the
actuarial rate of first cardiac event in the patients trea-
ted at the University of Michigan. The time to the first
cardiac event was calculated from the initiation of
radiotherapy. Patients without a cardiac event were
censored on the date of their death or last contact.
Relations between potential risk factors and act-
uarial rate of first cardiac event were analyzed using
the product-limit method of Kaplan and Meier and
the log-rank test statistic. To develop the best multi-
variate model for each endpoint, all characteristics
were offered simultaneously to a single Cox propor-
tional hazards regression model using a backward
elimination algorithm for variable inclusion. Charac-
teristics found to be at least marginally significant
(P < .1) were retained and compared with bivariate
analyses for evidence of confounding. As none was
found, final models only retained significant charac-
teristics, with significance defined by the usual P-value
less then 5% criterion. Possible 2-way interactions
between significant characteristics were also explored.
RESULTS
Of the 867 cases reviewed, 841 patients had medical
records sufficient for cardiovascular event follow-up.
Of these patients, 7 were excluded from analysis
because each of these patients received an additional
course of RT to the chest, either before or after treat-
ment of their primary breast cancers, for treatment of
other cancers, nonmalignant conditions, or breast
cancer recurrence. This left 834 patients analyzable for
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time to first cardiovascular event. The median follow-
up time for this population was 6.8 years (range, 1
month to 20.3 years). Excluded cases (n ¼ 33) were
similar to the analyzable sample for age, race, and
radiation dose administered to the breast. For an addi-
tional 6 patients, medical records could not identify
the patient’s racial group. Therefore, 828 patients,
comprising 6232 person-years, were used for compari-
son to the general population’s expected cardiovascu-
lar events rates and for calculation of SIRs.
Of the analyzable sample (N ¼ 834), 795 received
radiation therapy to 1 breast alone. In the analyses
that follow below, results based on the full set of 834
cases are presented where possible. Exceptions
include the calculations of SIRs and time-to-event
analyses that consider the laterality of the radiother-
apy treatment, where 828 and 795 patients are con-
sidered, respectively.
Demographic characteristics of the patient popu-
lation, cardiovascular risk factors, and characteristics
of breast cancer treatment are detailed in Table 1.
Median patient age at time of RT was 55.7 years
(range, 21.7–88.5 years).
Overall, 12 (1.4%) patients had at least 1 MI on
follow-up and 20 (2.4%) patients had at least 1 MI or
CAD requiring intervention on follow-up. Of the
patients with MI, all had a single event. When con-
sidering either MI or CAD requiring intervention, and
defining ‘‘event’’ as a single episode in terms of time
(during which a patient might have had both an MI
and an intervention), 18 patients had a single event,
1 had 2 events, and 1 had 3 events.
The median age at first cardiac event (either MI
or CAD requiring intervention) was 75.9 years (range,
43.1–91.5). The median interval from initiation of RT
to occurrence of the first cardiac event was 3.7 years
(range, 13 days to 15.4 years).
The overall risks of cardiac events were lower
than those in the age-matched control population.
The SIR of MI was 0.44 (95% CI: 0.21–0.70). The SIR
of MI or CAD requiring intervention was 0.50 (95%
CI: 0.27–0.68).
Figure 1 shows the cumulative incidence of MI
and Figure 2 shows the cumulative incidence of car-
diac events (either MI or CAD requiring interven-
tion), by laterality, during follow-up for the 795
patients in the University of Michigan series treated
with RT to 1 side. At 10 years of follow-up the overall
cumulative risk was 1.2% for MI and 2.7% for MI or
CAD requiring intervention.
TABLE 1
Characteristics of 834 Early-Stage Breast Cancer Patients Treated
With Breast-Conserving Surgery and Radiation Therapy at the
University of Michigan Hospital From 1984–2000
Characteristic No.



























* Active smoking defined as smoking at the time of radiotherapy (RT) commencement or quit date
<2 years before RT commencement.
y Adjuvant treatment defined as treatment with a systemic agent within 1 year of breast cancer diagnosis.
FIGURE 1. Cumulative incidence of first posttreatment myocardial infarc-
tion following breast-conserving surgery and radiotherapy for breast cancer,
stratified by the laterality of the treated breast.
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The occurrence of first MI was strongly associ-
ated with the age of the patient at breast cancer treat-
ment (hazard ratio [HR] ¼ 1.11, 95% CI: 1.05–1.17,
P ¼ .0004). The occurrence of first MI or CAD requir-
ing intervention was also strongly associated with the
age of the patient at breast cancer treatment
(HR ¼ 1.09, 95% CI: 1.05–1.14, P < .0001). Bivariate
associations for other baseline risk factors and clinical
and treatment characteristics, after adjustment for the
patient’s age at breast cancer treatment, are presented
in Table 2. There was no significant relation between
the incidence of cardiac events and tamoxifen or che-
motherapy administration. Factors significantly as-
sociated with the cumulative incidence of first MI
included diabetes mellitus, smoking, and laterality of
the irradiated breast. The only factor significantly
associated with the incidence of first MI or CAD
requiring intervention was active smoking, although
diabetes mellitus also trended toward significance.
On multivariate analysis, as shown in Table 3,
age, diabetes mellitus, active smoking, and laterality
of the treated breast remained significant predictors
of MI. Age and active smoking were the only signifi-
cant predictors of MI or CAD requiring intervention.
DISCUSSION
Techniques of radiation therapy have evolved dramati-
cally over the past several decades.23 By the 1980s,
most radiation oncologists had abandoned cobalt units
and outdated techniques such as deep tangents and en
face ‘hockey stick’ fields and began routinely to treat
breast cancer patients with standard tangents with
megavoltage linear accelerators. In more recent years,
some centers also began to use 3D CT-based planning
for left-sided breast cancers.24 3D planning may be par-
ticularly useful for minimizing cardiac irradiation
because it allows for quantification of heart dose and
greater planning flexibility to utilize off-axis fields and
exploit the angles of treatment based on each patient’s
unique geometry. However, the use of CT-planning for
breast cancer has only slowly become more widespread
in clinical practice. Indeed, a recent analysis of patterns
FIGURE 2. Cumulative incidence of first posttreatment myocardial infarction
and coronary artery disease requiring intervention following breast-conserving
surgery and radiotherapy for breast cancer, stratified by the laterality of the
treated breast.
TABLE 2
Hazard Ratios of Various Cardiovascular Risk Factors and
Treatment-Related Characteristics for First Cardiac Event,
Adjusted for Patient Age at Breast Cancer Treatment
Characteristic
MI alone






Hypertension 1.51 (0.43–5.25) .51 1.21 (0.48–3.07) .69
Diabetes mellitus 3.84 (1.07–13.78) .04 2.63 (0.91–7.64) .07
Smoking, ever 3.28 (1.03–10.44) .04 1.53 (0.62–3.76) .36
Smoking, active 5.68 (1.55–20.74) .009 3.34 (1.15–9.72) .03
Hypercholesterolemia 0.49 (0.11–2.25) .36 1.07 (0.41–2.77) .90
Previous coronary artery disease 2.64 (0.75–9.29) .13 1.77 (0.62–5.05) .29
Atrial fibrillation 2.43 (0.30–19.87) .41 1.39 (0.18–10.63) .75
Adjuvant tamoxifen 0.80 (0.25–2.58) .70 0.87 (0.35–2.12) .75
Tamoxifen use ever 0.70 (0.22–2.24) .54 0.76 (0.31–1.84) .54
Left-sided RT* 9.07 (1.16–71.18) .04 1.56 (0.61–3.98) .35
Adjuvant Chemotherapy 1.09 (0.21–5.79) .92 1.36 (0.40–4.62) .63
MI indicates myocardial infarction; CAD, coronary artery disease; RT, radiotherapy.
* Bilateral cases excluded, leaving a sample size of 795.
TABLE 3
Best Multivariate Models for First Posttreatment Cardiac Event
Characteristic First MI* First MI or Intervention for CAD
Age, continuous 1.12 (1.04–1.20) 1.11 (1.06–1.16)
P .002 <.001
Diabetes
Yes vs no 4.42 (1.13–17.31)
P .03
Smoker, active
Yes vs no 6.95 (1.83–26.33) 3.34 (1.15–9.72)
P .004 .03
Treated breast
Left vs right 7.92 (1.01–62.28)
P .05
MI indicates myocardial infarction; CAD, coronary artery disease.
* Bilateral cases were excluded leaving a sample size of 795 cases.
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of care in 1998–1999 documented CT planning use in
22.9% of breast cancer cases, compared with 9% in
1993–1994.25 More recently, even more sophisticated
techniques—including intensity modulated radiation
therapy,26 breathing controlled radiation,27–31 and other
innovations32—have also been explored.
In this series of patients treated at the University
of Michigan over the past 2 decades the overall risks
of MI and CAD requiring intervention were signifi-
cantly lower than the expected rates calculated using
the NHDS. Nevertheless, we did find a statistically
significant increase in the risk of MI in patients irra-
diated to the left breast, compared with those irra-
diated to the right. Given the size of this single
institution’s series and the small number of events,
the size of the confidence interval surrounding the
hazard ratio is quite large. Moreover, the absolute
risk is extremely low, such that even a large increase
in relative risk contributes to an absolute risk eleva-
tion that is small in magnitude. Nevertheless, given
other studies suggesting that the cardiac toxicity
from RT is not fully manifest until many years after
exposure,33 it is noteworthy that this study, with a
median follow-up of 7 years, did detect a difference
between left- and right-sided treatment. Further-
more, this study is consistent with the experience
recently reported by the University of Pennsylvania,
where left-sided patients treated with tangential irra-
diation were again found to have significantly higher
rates of chest pain, CAD, and MI.12
Therefore, this finding supports further investiga-
tion of the potential impact of CT planning in allowing
quantification and reduction of cardiac dose, as com-
pared with the clinical planning utilized for the treat-
ment of the vast majority of patients in this study. In
light of the data that even patients treated with CT
planning may have significant perfusion defects,15 it is
important to obtain long-term clinical follow-up in
patients treated with this technique. This is particularly
important because the use of chemotherapeutic agents
such as doxorubicin and trastuzumab in the modern
era may compound any radiation-induced damage that
may occur. In addition, it will be valuable to compare
these results with those obtained using techniques
such as intensity modulation and breathing control,
which may be valuable in further minimizing the long-
term cardiac risks faced by breast cancer patients, par-
ticularly with left-sided disease. Ideally, these clinical
outcomes should be assessed in the context of a rando-
mized clinical trial.
Patients in this series had a lower risk of MI and
CAD requiring intervention than expected from com-
parison to a matched control population. This sug-
gests that survivors of early-stage breast cancer may
have a lower risk of ischemic cardiac events com-
pared with the general American population. This is
consistent with the finding of the only other pub-
lished study exploring MI rates in breast cancer
patients of which we are aware.13 The mechanisms
for this finding have yet to be established, but hypo-
theses have been proposed.
One possibility is that the use of hormonal therapy
in many of these patients may lower their cardiac risk,
although the net effects of selective estrogen receptor
modulators upon cardiac risk have yet to be clearly
established.34–40 Another possibility is that endogenous
estrogens, which play a pathogenetic role in the devel-
opment of breast cancer, may be protective against car-
diac disease. Yet another interesting idea is that IGF-1,
which has also been implicated in the pathogenesis of
breast cancer,41 may have vasculoprotective effects.42–44
Further study is necessary to explore each of these pos-
sibilities, which may have important implications for
the treatment of both breast cancer and cardiac disease.
However, it is important to note the potential lim-
itations of the comparison of the University of Michi-
gan series to a control population drawn from the
NHDS. First, because of a change in the ICD-9 coding
system in 1989, only the years 1989–2003 could be used
in calculating expected rates, whereas observed rates
were drawn from a cohort treated between the years
1984–2000 (and followed through 2004). Therefore, to
some extent, a simple increase in the incidence of CAD
over time would itself contribute to a finding of a lower
rate of CAD in the observed population than expected,
insofar as the expected rates were calculated from a
population derived from later years. Still, it does not
appear that the age-adjusted incidence of CAD has
increased in the past 2 decades.45,46 Furthermore, this
study relies heavily on the accuracy of the NHDS sam-
pling strategy and US Census Bureau’s yearly popula-
tion estimates. It is important to note that there was
considerable variability from year to year in the mean
rates of cardiac events in these surveys, when summed
by 5-year age group and race categories, as used to con-
struct the population parameters for our calculations.
Therefore, although the strongly significant finding sug-
gests that rates of MI and CAD requiring intervention
are likely lower among the patients in our series than
expected, the actual magnitude of the difference in
observed and expected rates may be overestimated due
to these methodological issues in the calculation of
expected rates.
Conclusions
In summary, in this series of patients treated for
early-stage breast cancer with breast-conserving sur-
gery and adjuvant RT at the University of Michigan,
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the cumulative incidence of MI and CAD requiring
intervention was very low, and significantly lower
than that which would have been expected based on
the patients’ age, sex, and race alone. There appears to
be some increased risk for patients treated to the left
side of the chest, compared with those treated to the
right, but the absolute magnitude of the increased
risk, at least during the first decade after treatment, is
low. Nevertheless, these findings support further as-
sessment of clinical outcomes when newer techniques
of CT planning are employed, as well as investigation
of the potential role of innovative techniques such as
intensity modulated radiotherapy and breathing con-
trolled radiation. Such techniques may be valuable in
reducing the volume of heart irradiated and, therefore,
the long-term mortality and morbidity that may result
from this integral part of the conservative treatment of
breast cancer, particularly in patients with left-sided
disease.
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